Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCCH2308 safety study of antibiotics + fecal microbiota transplantation before immune checkpoint inhibitor therapy in gastrointestinal cancers
jRCTs031240170Recruiting
- Sponsor
- Metagen Therapeutics, Inc.
- Start
- Jun 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of amoxicillin, fosfomycin, metronidazole, allogeneic fecal microbiota, nivolumab and 5 more in Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma, hepatocellular carcinoma (HCC) and 1 more, sponsored by Metagen Therapeutics, Inc. Primary endpoint: Treatment-limiting toxicity incidence rate. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomahepatocellular carcinoma (HCC)biliary cancer
Beyond the preview
Go deeper on jRCTs031240170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240170.